MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at…
MaaT PharmaDecember 8, 2025
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…
MaaT PharmaMay 14, 2025
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013…
MaaT PharmaJanuary 8, 2025
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting…
MaaT PharmaNovember 7, 2024
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes Completion…
MaaT PharmaNovember 5, 2024
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…
MaaT PharmaOctober 15, 2024
